Bacterial Outer Membrane Vesicles (OMVs)-based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV

Overview

Journal Vaccines (Basel)

Date 2019 May 31

PMID 31141982

Citations 26

Authors

Mahmoud M Shehata

Ahmed Mostafa

Lisa Teubner

Sara H Mahmoud

Ahmed Kandeil

Rabeh Elshesheny

Renate Frantz

Luigi La Pietra

Stephan Pleschka

Ahmed Osman

Ghazi Kayali

Trinad Chakraborty

Mohamed A Ali

Mobarak Abu Mraheil

Affiliations

Soon will be listed here.

Abstract

Vaccination is the most functional medical intervention to prophylactically control severe diseases caused by human-to-human or animal-to-human transmissible viral pathogens. Annually, seasonal influenza epidemics attack human populations leading to 290-650 thousand deaths/year worldwide. Recently, a novel Middle East Respiratory Syndrome Coronavirus emerged. Together, those two viruses present a significant public health burden in areas where they circulate. Herein, we generated a bacterial outer membrane vesicles (OMVs)-based vaccine presenting the antigenic stable chimeric fusion protein of the H1-type haemagglutinin (HA) of the pandemic influenza A virus (H1N1) strain from 2009 (H1N1pdm09) and the receptor binding domain (RBD) of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (OMVs-H1/RBD). Our results showed that the chimeric antigen could induce specific neutralizing antibodies against both strains leading to protection of immunized mice against H1N1pdm09 and efficient neutralization of MERS-CoV. This study demonstrate that OMVs-based vaccines presenting viral antigens provide a safe and reliable approach to protect against two different viral infections.

Citing Articles

Hybrid response to SARS-CoV-2 and C after an OMV-adjuvanted immunization in mice and their offspring.

Portilho A, Hermes Monteiro da Costa H, Grando Guereschi M, Prudencio C, De Gaspari E Hum Vaccin Immunother. 2024; 20(1):2346963.

PMID: 38745461 PMC: 11789737. DOI: 10.1080/21645515.2024.2346963.

Bacteria-derived extracellular vesicles: endogenous roles, therapeutic potentials and their biomimetics for the treatment and prevention of sepsis.

Effah C, Ding X, Drokow E, Li X, Tong R, Sun T Front Immunol. 2024; 15:1296061.

PMID: 38420121 PMC: 10899385. DOI: 10.3389/fimmu.2024.1296061.

Outer Membrane Vesicle Vaccine Platforms.

Micoli F, Adamo R, Nakakana U BioDrugs. 2023; 38(1):47-59.

PMID: 37796436 PMC: 10789842. DOI: 10.1007/s40259-023-00627-0.

The Two Faces of Bacterial Membrane Vesicles: Pathophysiological Roles and Therapeutic Opportunities.

Thapa H, Ebenberger S, Schild S Antibiotics (Basel). 2023; 12(6).

PMID: 37370364 PMC: 10295235. DOI: 10.3390/antibiotics12061045.

Outer membrane vesicles as versatile tools for therapeutic approaches.

Zingl F, Leitner D, Thapa H, Schild S Microlife. 2023; 2:uqab006.

PMID: 37223254 PMC: 10117751. DOI: 10.1093/femsml/uqab006.

References

POTTER C . A history of influenza. J Appl Microbiol. 2001; 91(4):572-9. DOI: 10.1046/j.1365-2672.2001.01492.x. View

Raetz C, Whitfield C . Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002; 71:635-700. PMC: 2569852. DOI: 10.1146/annurev.biochem.71.110601.135414. View

Bahgat M, Kutkat M, Nasraa M, Mostafa A, Webby R, Bahgat I . Characterization of an avian influenza virus H5N1 Egyptian isolate. J Virol Methods. 2009; 159(2):244-50. DOI: 10.1016/j.jviromet.2009.04.008. View

Neumann G, Noda T, Kawaoka Y . Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009; 459(7249):931-9. PMC: 2873852. DOI: 10.1038/nature08157. View

Lessler J, Reich N, Cummings D, Nair H, Jordan H, Thompson N . Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school. N Engl J Med. 2010; 361(27):2628-36. DOI: 10.1056/NEJMoa0906089. View

Roy N, Barman S, Ghosh A, Pal A, Chakraborty K, Das S . Immunogenicity and protective efficacy of Vibrio cholerae outer membrane vesicles in rabbit model. FEMS Immunol Med Microbiol. 2010; 60(1):18-27. DOI: 10.1111/j.1574-695X.2010.00692.x. View

Lynch M . Evolution of the mutation rate. Trends Genet. 2010; 26(8):345-52. PMC: 2910838. DOI: 10.1016/j.tig.2010.05.003. View

Bommakanti G, Citron M, Hepler R, Callahan C, Heidecker G, Najar T . Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A. 2010; 107(31):13701-6. PMC: 2922242. DOI: 10.1073/pnas.1007465107. View

Zollinger W, Poolman J, Maiden M . Meningococcal serogroup B vaccines: will they live up to expectations?. Expert Rev Vaccines. 2011; 10(5):559-61. PMC: 3985070. DOI: 10.1586/erv.11.41. View

10.

Van der Ley P, Dobbelsteen G . Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum Vaccin. 2011; 7(8):886-90. DOI: 10.4161/hv.7.8.16086. View

11.

Raj V, Mou H, Smits S, Dekkers D, Muller M, Dijkman R . Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013; 495(7440):251-4. PMC: 7095326. DOI: 10.1038/nature12005. View

12.

Parry J . H7N9 avian flu infects humans for the first time. BMJ. 2013; 346:f2151. DOI: 10.1136/bmj.f2151. View

13.

Mostafa A, Kanrai P, Ziebuhr J, Pleschka S . Improved dual promotor-driven reverse genetics system for influenza viruses. J Virol Methods. 2013; 193(2):603-10. DOI: 10.1016/j.jviromet.2013.07.021. View

14.

Shi W, Shi Y, Wu Y, Liu D, Gao G . Origin and molecular characterization of the human-infecting H6N1 influenza virus in Taiwan. Protein Cell. 2013; 4(11):846-53. PMC: 4875453. DOI: 10.1007/s13238-013-3083-0. View

15.

Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G . A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One. 2013; 8(12):e81587. PMC: 3852489. DOI: 10.1371/journal.pone.0081587. View

16.

Chen H, Yuan H, Gao R, Zhang J, Wang D, Xiong Y . Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet. 2014; 383(9918):714-21. DOI: 10.1016/S0140-6736(14)60111-2. View

17.

Khanna M, Sharma S, Kumar B, Rajput R . Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development. Biomed Res Int. 2014; 2014:546274. PMC: 4055638. DOI: 10.1155/2014/546274. View

18.

Fantappie L, De Santis M, Chiarot E, Carboni F, Bensi G, Jousson O . Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen. J Extracell Vesicles. 2014; 3. PMC: 4131003. DOI: 10.3402/jev.v3.24015. View

19.

Mamat U, Wilke K, Bramhill D, Schromm A, Lindner B, Kohl T . Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins. Microb Cell Fact. 2015; 14:57. PMC: 4404585. DOI: 10.1186/s12934-015-0241-5. View

20.

Mostafa A, Kanrai P, Ziebuhr J, Pleschka S . The PB1 segment of an influenza A virus H1N1 2009pdm isolate enhances the replication efficiency of specific influenza vaccine strains in cell culture and embryonated eggs. J Gen Virol. 2016; 97(3):620-631. DOI: 10.1099/jgv.0.000390. View